Clinical involvement and protein expression in individuals with the FMR1 premutation

Area of Science:

• Genetics
• Neuroscience
• Molecular Biology

Background:

• Fragile X premutation carriers are typically asymptomatic, but some exhibit clinical symptoms like learning difficulties or cognitive deficits.
• The underlying cause of clinical manifestations in premutation carriers remains unclear.
• Premutation alleles are generally associated with normal Fragile X Messenger Ribonucleoprotein (FMRP) levels.

Observation:

• This study investigated six individuals with the fragile X premutation to explore the spectrum of phenotypic involvement.
• One individual with the premutation had intellectual disability unrelated to FMR1 gene dysfunction.
• Other cases displayed varying degrees of FMR1 gene dysfunction, assessed by FMRP and FMR1 mRNA levels, alongside fragile X-associated clinical features.

Findings:

• Two cases showed significantly reduced FMRP expression coupled with elevated FMR1 mRNA levels.
• These two cases also presented with moderate cognitive deficits.
• FMRP levels serve as a useful biomarker for determining FMR1 gene dysfunction as the cause of clinical involvement in premutation patients.

Implications:

• Understanding the relationship between FMR1 gene dysfunction and clinical presentation in premutation carriers is crucial for accurate diagnosis.
• FMRP level assessment can aid in differentiating between fragile X-related symptoms and other causes of cognitive impairment.
• This research highlights the importance of molecular diagnostics in managing fragile X-associated disorders.